vinpocetine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| vinca alkaloids | 2828 | 42971-09-5 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
whole issue of Arzneim Forsch (23 articles) discuss this drug; Arzneim Forsch 26(10a);1976; RN given refers to parent cpd with unspecified isomeric designation
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 15 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 6.70 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 2.08 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 6.10 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.02 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 4.83 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
None
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Psychomotor retardation | 52.53 | 45.83 | 11 | 489 | 3222 | 46682340 |
| Bradykinesia | 50.29 | 45.83 | 11 | 489 | 3955 | 46681607 |
| Flat affect | 49.35 | 45.83 | 9 | 491 | 1289 | 46684273 |
| Tension | 47.90 | 45.83 | 10 | 490 | 2882 | 46682680 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N06BX18 | NERVOUS SYSTEM PSYCHOANALEPTICS PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS Other psychostimulants and nootropics |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D018696 | Neuroprotective Agents |
| MeSH PA | D018697 | Nootropic Agents |
| MeSH PA | D010726 | Phosphodiesterase Inhibitors |
| MeSH PA | D020011 | Protective Agents |
| MeSH PA | D014665 | Vasodilator Agents |
Drug Use (View source of the data)
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Dementia | indication | 52448006 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 7.03 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A | Enzyme | IC50 | 5.10 | CHEMBL | |||||
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C | Enzyme | INHIBITOR | IC50 | 4.30 | IUPHAR | ||||
| Phosphodiesterase 1 | Enzyme | IC50 | 4.72 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4024909 | VUID |
| N0000171574 | NUI |
| D01371 | KEGG_DRUG |
| 4024909 | VANDF |
| C0124496 | UMLSCUI |
| CHEBI:32297 | CHEBI |
| CHEMBL71752 | ChEMBL_ID |
| DB12131 | DRUGBANK_ID |
| 443955 | PUBCHEM_CID |
| C013983 | MESH_SUPPLEMENTAL_RECORD_UI |
| 4046 | INN_ID |
| 543512OBTC | UNII |
| 5285 | IUPHAR_LIGAND_ID |
| 24506 | RXNORM |
| 005991 | NDDF |
| 716059001 | SNOMEDCT_US |
Pharmaceutical products:
None